James Gordon CFA
Stock Analyst at Barclays
(4.59)
# 848
Out of 5,099 analysts
141
Total ratings
76.3%
Success rate
18.1%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,750p | 1,828p | -4.24% | 36 | Nov 3, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €83.00 → €90.00 | €80.98 | +11.14% | 8 | Nov 2, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,000p → 17,000p | 13,760p | +23.55% | 21 | Nov 2, 2026 | |
| SWX: SDZ Sandoz Group AG | Reiterated: Buy | CHF 93.00 | CHF 82.78 | +12.35% | 12 | Oct 29, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 130.00 → CHF 125.00 | CHF 131.50 | -4.94% | 14 | Oct 28, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 220.00 → CHF 230.00 | CHF 189.00 | +21.69% | 26 | Oct 23, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 410.00 → CHF 430.00 | CHF 391.00 | +9.97% | 14 | Sep 8, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Upgraded: Hold | 1,350p → 1,700p | 1,743p | -2.47% | 4 | Sep 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Sell | €22.00 | €28.72 | -23.40% | 3 | Sep 8, 2026 | |
| GMAB Genmab | Reiterated: Buy | n/a | $55.52 | - | 1 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $950 | $901.12 | +5.42% | 1 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 530.00 | kr 477.40 | +11.02% | 1 | Jul 3, 2026 |
GSK plc
Nov 3, 2026
Reiterated: Sell
Price Target: 1,750p
Current: 1,828p
Upside: -4.24%
Sanofi
Nov 2, 2026
Reiterated: Hold
Price Target: €83.00 → €90.00
Current: €80.98
Upside: +11.14%
AstraZeneca PLC
Nov 2, 2026
Reiterated: Buy
Price Target: 16,000p → 17,000p
Current: 13,760p
Upside: +23.55%
Sandoz Group AG
Oct 29, 2026
Reiterated: Buy
Price Target: CHF 93.00
Current: CHF 82.78
Upside: +12.35%
Novartis AG
Oct 28, 2026
Reiterated: Hold
Price Target: CHF 130.00 → CHF 125.00
Current: CHF 131.50
Upside: -4.94%
Galderma Group AG
Oct 23, 2026
Reiterated: Buy
Price Target: CHF 220.00 → CHF 230.00
Current: CHF 189.00
Upside: +21.69%
Roche Holding AG
Sep 8, 2026
Reiterated: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 391.00
Upside: +9.97%
Hikma Pharmaceuticals PLC
Sep 8, 2026
Upgraded: Hold
Price Target: 1,350p → 1,700p
Current: 1,743p
Upside: -2.47%
Lakefront Biotherapeutics NV
Sep 8, 2026
Reiterated: Sell
Price Target: €22.00
Current: €28.72
Upside: -23.40%
Genmab
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $55.52
Upside: -
Jul 24, 2026
Reiterated: Buy
Price Target: $950
Current: $901.12
Upside: +5.42%
Jul 3, 2026
Reiterated: Buy
Price Target: kr 530.00
Current: kr 477.40
Upside: +11.02%